Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Gov't to Earmark ¥79.0 Bil. to Promote Development of Unapproved Drugs
May 4, 2009
- Kyowa Kirin Aiming at Becoming Global Specialty Pharma
May 4, 2009
- R&D NEWS IN BRIEF
May 4, 2009
- Shionogi Expands Support Systems for Female MRs
May 4, 2009
- Pharmacists Should Be Encouraged to Dispense More Generics
May 4, 2009
- GSK to Lead Respiratory Drug Market with Adoair
May 4, 2009
- JSHP to More Actively Cooperate with the Use of More Generics
May 4, 2009
- Toyota Tsusho to Represent ChemRoutes in Japan
May 4, 2009
- Patient Education Important to Promote Use of Generics
May 4, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 27, 2009
- No Progress on Discussions on Online Sales of OTC Drugs
April 27, 2009
- Taiyo Acquires Schering-Plough's Kasukabe Plant
April 27, 2009
- Korosho Proposes New Policy for Approval of Generics of Drugs Covered by Valid Use Patents
April 27, 2009
- R&D NEWS IN BRIEF
April 27, 2009
- CoreMed Expands Drug Development Support Services in Europe
April 27, 2009
- Potential Biomarker for Oxaliplatin Discovered: Prof. Tanigawara
April 27, 2009
- REGULATORY NEWS IN BRIEF
April 27, 2009
- Majority of Major Drug Firms Increase Hiring of New Graduates in 2009
April 27, 2009
- Coefficients for Generics for DPC Hospitals May Be Introduced
April 27, 2009
- Yokohama Clinic Starts Cancer Therapy Using Dendritic Cells
April 27, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…